EBD Group is part of the KNect365 of Informa PLC


This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
Partnerships in Cell and Gene Therapy Partnerships in Cell and Gene Therapy Partnerships in Cell and Gene Therapy Partnerships in Cell and Gene Therapy
Share/Follow Us
Share this:
Follow this event:
Subscribe to our newsletters:

Partnerships in Cell and Gene Therapies Press Releases



partnering360:Insight Latest headlines from partnering360:Insight

November 13, 2017 Breaking down walls: Big pharma explores new models for collaboration Innovation centers have become the beachhead for large pharma seeking early access to innovation, with Johnson & Johnson, Bayer and Sanofi each offering a different version in different geographies, underscoring the importance that location has taken on recently. more ►

November 13, 2017 Digital Health faces formidable hurdles in chronic disease management Bringing healthcare into the digital age would create a greenfield opportunity, opening vast opportunities for devices and drugs.  Yet before companies can start open field running through the sector, they face a series of formidable hurdles that must be overcome: patient acceptance, adoption by physicians, integration with healthcare systems and payers willing to pay. more ►

November 9, 2017 China 2.0: Surprise reform from highest authorities. Is it real this time? Not known for irrational exuberance, Chinese life science executives stopped just short of excitement at BIO-Europe® 2017 speaking about the unexpected news that came down from the nation's highest authorities in mid-October that China's FDA (CFDA) has reformed its rules for regulatory approvals. more ►

November 9, 2017 Biologic platform deals out of Europe take the lead in 2017 With two months yet to go in 2017, R&D-stage dealmaking is looking to finish near 2016 levels, both in number and in total upfront dollars, remaining below peak levels seen in 2014 and 2015, according to David Thomas, Senior Director for Industry Research & Analysis with the Biotechnology Innovation Organization (BIO), based in Washington, DC. more ►

November 9, 2017 Dealmaking in 2017 points to winning trends for near-term opportunities No one likes to see the indicators for dealmaking slow down.  For one thing, it is hypothesis generating: Is the market stalled? Is it a slump? Is it the beginning of the end? Is it the start of a new cycle? To get a handle on what is working in life science partnering, participants at BIO-Europe 2017 took a deep dive into deals of the past year looking for trends, and for signs of success that point the way forward.  more ►



Arrow Up

Follow this event:
Home | Contact Us | Site Map
See more upcoming conferences ►

EBD Group's Family of Events

© 2009–2016 EBD Group
Privacy Policy and Cookies
Terms of Use